Holen Sie sich die Stockscreener-App
3.62
3.43%
0.12
Vorhandelsmarkt:
3.61
-0.01
-0.28%
Schlusskurs vom Vortag:
$3.50
Offen:
$3.54
24-Stunden-Volumen:
3.98M
Relative Volume:
0.94
Marktkapitalisierung:
$934.64M
Einnahmen:
$427.68M
Nettoeinkommen (Verlust:
$-58.06M
KGV:
-15.20
EPS:
-0.2382
Netto-Cashflow:
$-37.50M
1W Leistung:
+6.47%
1M Leistung:
-6.94%
6M Leistung:
-31.83%
1J Leistung:
-41.80%
1-Tages-Spanne:
$3.47
$3.63
1-Wochen-Bereich:
$3.33
$3.63
52-Wochen-Spanne:
$3.33
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Firmenname
Ardelyx Inc
Sektor
Branche
Telefon
510-745-7047
Adresse
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
3.62 | 924.31M | 427.68M | -58.06M | -37.50M | -0.2382 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-09-03 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-02 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2025-03-04 | Eingeleitet | BTIG Research | Buy |
| 2024-11-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2023-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-25 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-11-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Herabstufung | Jefferies | Buy → Hold |
| 2021-07-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-23 | Eingeleitet | Wedbush | Outperform |
| 2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Fortgesetzt | Citigroup | Buy |
| 2020-02-18 | Fortgesetzt | Jefferies | Buy |
| 2020-02-12 | Eingeleitet | Citigroup | Buy |
| 2020-02-10 | Eingeleitet | Cowen | Outperform |
| 2019-04-08 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-24 | Eingeleitet | Jefferies | Buy |
| 2018-03-19 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-29 | Bestätigt | Citigroup | Buy |
| 2017-11-22 | Bestätigt | Ladenburg Thalmann | Buy |
| 2017-10-17 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-03-31 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-03-09 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-03 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Ardelyx Inc Aktie (ARDX) Neueste Nachrichten
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’ - Stocktwits
Ardelyx (ARDX) Could Be 72% Undervalued Following Its September Investor Conference Run - simplywall.st
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug - Stocktwits
Ardelyx at cantor global healthcare conference: growth meets payer pressure - investing.com
ARDX: Profitability targeted by 2027 as IBSRELA and XPHOZAH drive growth amid payer and market shifts - TradingView
Ardelyx at cantor global healthcare conference: growth meets payer pressure By Investing.com - Investing.com UK
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits
Ardelyx Inc (ARDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ardelyx (ARDX) Has Investors Looking Closer, But What Is Driving The Attention? - simplywall.st
Ardelyx CHRO James Brady sells $58,378 in stock By Investing.com - Investing.com Nigeria
Ardelyx CHRO James Brady sells $58,378 in stock - Investing.com
Ardelyx to Participate in Upcoming Investor Conferences - Yahoo Finance
Have Insiders Sold Ardelyx Shares Recently? - simplywall.st
Ardelyx chief patient officer sells $41,419 in stock By Investing.com - Investing.com Australia
Ardelyx chief patient officer sells $41,419 in stock - Investing.com India
Ardelyx CCO Eric Foster sells $33,022 in stock By Investing.com - Investing.com Canada
Ardelyx CCO Eric Foster sells $33,022 in stock - Investing.com India
Ardelyx CBO Mike Kelliher sells $29,921 in shares By Investing.com - Investing.com Canada
Ardelyx CEO Michael Raab sells $225,914 in ARDX stock By Investing.com - Investing.com Canada
Ardelyx chief technical officer John Bishop sells $76,173 in stock By Investing.com - Investing.com Canada
Ardelyx chief human resources officer sells $58,378 in stock By Investing.com - Investing.com Nigeria
Ardelyx chief technical officer John Bishop sells $76,173 in stock - Investing.com India
Ardelyx SVP Joseph Reilly sells $15,358 of company stock By Investing.com - Investing.com Nigeria
Ardelyx SVP Joseph Reilly sells $15,358 of company stock - Investing.com India
Ardelux CFO Susan Hohenleitner sells $6,009 in shares - investing.com
Ardelyx (ARDX) Cuts Guidance On Payer Hurdles As Fair Value Debate Heats Up - Yahoo Finance
Ardelyx (NASDAQ: ARDX) holder plans tax sale of vesting shares - Stock Titan
Ardelyx (NASDAQ: ARDX) exec plans 10,500-share RSU tax sale - Stock Titan
Ardelyx (NASDAQ: ARDX) insider plans $179K stock sale - Stock Titan
Ardelyx (NASDAQ: ARDX) plans RSU tax-cover sale of 10,500 shares - Stock Titan
Ardelyx (ARDX) exec to sell $18.9K in shares for RSU taxes - Stock Titan
Ardelyx (NASDAQ: ARDX) shareholder John Bishop plans 25,500-share sale - Stock Titan
Ardelyx (NASDAQ: ARDX) officer plans stock sales and tax-cover trades - Stock Titan
Ardelyx (ARDX) officer to sell 11,900 shares for RSU taxes - Stock Titan
334,115 Shares in Ardelyx, Inc. $ARDX Acquired by Clay Northam Wealth Management LLC - MarketBeat
Ardelyx (ARDX) Securities Investigation NoticeLevi & Korsinsky - Morningstar
Ardelyx (NASDAQ:ARDX) Sets New 52-Week LowHere's Why - MarketBeat
Ardelyx (ARDX) Earnings Update: EPS Falls Short of Its Estimate under the Current Snapshot; Investor Response: Shares Fall 2.61% at the CloseRevenue Inflection Point - vinanet.vn
Ardelyx (ARDX) Following Strong Results And Guidance Still Looks Undervalued - simplywall.st
ARDX Reiterates by Wedbush -- Price Target Maintained at $9.00 - GuruFocus
Exploring 3 High Growth Tech Stocks In The US Market - Sahm
Ardelyx Chief Commercial Officer Announces Upcoming Resignation - The Globe and Mail
Ardelyx (ARDX) Q2 2026 Earnings Call Transcript - AOL.com
Ardelyx, Inc. (ARDX) Latest Stock News & Headlines - Yahoo Finance
Wedbush Reiterates Outperform Rating for Ardelyx (NASDAQ:ARDX) - MarketBeat
Ardelyx Leads The Charge With These 3 Compelling Penny Stocks - Sahm
Finanzdaten der Ardelyx Inc-Aktie (ARDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ardelyx Inc-Aktie (ARDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Reilly Joseph James | See Remarks |
Aug 21 '26 |
Sale |
3.86 |
3,982 |
15,358 |
145,854 |
| Bishop John E | See Remarks |
Aug 21 '26 |
Sale |
3.86 |
19,750 |
76,174 |
317,095 |
| Brady James Parker | Chief Human Resources Officer |
Aug 21 '26 |
Sale |
3.86 |
15,136 |
58,378 |
245,930 |
| Foster Eric Duane | Chief Commercial Officer |
Aug 21 '26 |
Sale |
3.86 |
8,562 |
33,023 |
409,410 |
| Kelliher Mike | Chief Business Officer |
Aug 21 '26 |
Sale |
3.86 |
7,758 |
29,922 |
349,660 |
| Williams Laura A | Chief Patient Officer |
Aug 21 '26 |
Sale |
3.86 |
10,739 |
41,419 |
367,456 |
| RAAB MICHAEL | President & CEO |
Aug 21 '26 |
Sale |
3.86 |
58,574 |
225,914 |
1,619,792 |
0.14%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):